REGN

$REGN

Regeneron Pharmaceuticals

Biotech company known for Eylea and Dupixent immunology drugs.

Healthcare
$923.34
-22.19 (-2.35%)
Day Range$920.24 - $946.99
Prev Close$945.53

REGN key facts as of November 14, 2026

Latest AI research report
REGN: Growth, Valuation and Pipeline Risks (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Strong Buy (4 Strong Buy, 15 Buy, 9 Hold, 0 Sell, 1 Strong Sell) (as of November 1, 2026)
Analyst price target
$925.53 mean (range $756.00 to $1100.00) (as of November 20, 2026)
Sector
Healthcare
Analyst Rating
Strong Buy
19 Buy / 9 Hold / 1 Sell
Price Target
$925.53
0.2% upside
Subscribers
1
Tracking this ticker
Latest Report

Analysis from Nov 14, 2026

NEUTRAL

REGN: Growth, Valuation and Pipeline Risks

Regeneron’s recent earnings beat, Dupixent and Eylea franchises, and expanding pipeline offer meaningful growth drivers. Yet the shares are near their 52-week high, analyst target datasets disagree, and competition for Eylea remains a key risk.

Nov 14, 2026

REGN FAQ

What is StockAlpha's latest view on REGN?

StockAlpha's latest AI research report on Regeneron Pharmaceuticals (REGN), "REGN: Growth, Valuation and Pipeline Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Regeneron’s recent earnings beat, Dupixent and Eylea franchises, and expanding pipeline offer meaningful growth drivers. Yet the shares are near their 52-week high, analyst target datasets disagree, and competition for Eylea remains a key risk.

When was the REGN research last updated?

The most recent REGN report was published on November 14, 2026.

What do analysts expect for REGN?

As of November 1, 2026, the analyst consensus on REGN is Strong Buy (4 Strong Buy, 15 Buy, 9 Hold, 0 Sell, 1 Strong Sell). As of November 20, 2026, the analyst price target is $925.53 mean (range $756.00 to $1100.00).

Is this REGN research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring